

# **REGENERON PHARMACEUTICALS, INC.**

Annual Meeting of Shareholders  
Friday, June 10, 2022

## **Agenda**

- Call to Order
- Organization of Meeting and Introductions
- Election of Directors
- Ratification of Appointment of Independent Registered Public Accounting Firm
- Advisory Vote on Compensation of Named Executive Officers (Say-on-Pay Vote)
- Report of Inspector of Election
- Company Update
- Question-and-Answer Period
- Adjournment

# REGENERON PHARMACEUTICALS, INC.

Annual Meeting of Shareholders

Friday, June 10, 2022

## Conduct of Meeting

In fairness to all shareholders in attendance and in the interest of an orderly meeting, we ask you to honor the following rules of conduct:

1. The Company will cause the meeting to be recorded.
2. Shareholders and proxy holders may use the 16-digit control number that was furnished to them to log on to the virtual meeting website to submit questions during the meeting.
3. Questions submitted on the virtual meeting website will be grouped by topic and substantially similar questions will be combined and answered at once.
4. The business of the meeting will be taken up as set forth in the Agenda. When an item on the Agenda is before the meeting for consideration, questions and comments should be confined to that item.
5. If a shareholder or proxy holder has a question or comment not related to an Agenda item, an opportunity will be provided, as time permits, to present proper questions and comments during the question-and-answer period.
6. If there are any matters of individual concern to a shareholder or proxy holder, they should be raised after the meeting. You can contact the Company by telephone at (914) 847-7741 or e-mail at [invest@regeneron.com](mailto:invest@regeneron.com).
7. Derogatory references to persons or actions or comments that are disruptive or in bad taste will not be permitted.
8. The views, constructive comments, and criticisms of shareholders are welcome, but the purpose of the meeting will be observed, and the Chairman will not address submitted questions/comments that:
  - are irrelevant to the business of the Company;
  - relate to the conduct of the Company's ordinary business operations;
  - relate to pending or threatened litigation;
  - include derogatory references or other comments that are not in good taste;
  - relate to personal grievances;
  - are unduly prolonged; or
  - are in substance repetitious of statements previously made.